Otsuka Holdings Co., Ltd.

4578

JP3188220002

Pharmaceuticals

Delayed Japan Exchange Other stock markets 02:00:00 2024-04-23 am EDT			5-day change	1st Jan Change
6,340 ^JPY	+0.28%		+0.06%	+19.87%

Apr. 09	H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy	MT
Mar. 29	Otsuka Holdings Disposes of 2.32 Billion Yen Worth of Shares as Restricted Stock Compensation	MT

Otsuka : Announcement of Changes in Company Officers at Otsuka Pharmaceutical Co., Ltd.

December 12, 2019 at 09:31 am EST

Otsuka Holdings Co., Ltd. and its subsidiary Otsuka Pharmaceutical Co., Ltd. announce that the changes described below have been made to the composition of company officers at Otsuka Pharmaceutical, pursuant to decisions by the boards of directors at Otsuka Holdings and at Otsuka Pharmaceutical on December 11 and December 9, respectively.

The change of company officers will be decided formally at the general shareholders meeting of Otsuka Pharmaceutical on March 10, 2020, and the subsequent board meeting.

Contact:

Tel: +81 (0)3-6717-1410

Latest news about Otsuka Holdings Co., Ltd.

H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy	Apr. 09	MT
Otsuka Holdings Disposes of 2.32 Billion Yen Worth of Shares as Restricted Stock Compensation	Mar. 29	MT
EU Commission Green-lights Lundbeck, Otsuka's Abilify Maintena as Maintenance Treatment of Schizophrenia	Mar. 27	MT
Jefferies Adjusts Otsuka Holdings’ Price Target to 7,400 Yen From 6,800 Yen, Keeps at Buy	Mar. 18	MT
Sumitomo Pharma Amends Collaboration Agreement with Otsuka Pharmaceutical	Mar. 17	MT
VIE STYLE, Inc. announced that it has received ¥305 million in funding from Otsuka Holdings Co., Ltd., KAYAC Inc., Taisho Pharmaceutical Holdings Co., Ltd., Towa Pharmaceutical Co., Ltd., PE&HR Co., Ltd., Murata Manufacturing Co., Ltd. and other investors	Mar. 06	CI
IBio Sells Preclinical PD-1 Antagonist Antibody Program to Otsuka	Feb. 26	DJ
Otsuka Holdings' Attributable Profit Down 9.2% 2023 On Impairment Losses	Feb. 16	MT
Otsuka Holdings Co., Ltd. Provides Year-End Dividend Guidance for the Fiscal Year Ending December 31, 2024	Feb. 16	CI
Otsuka Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending December 31, 2024	Feb. 16	CI
Otsuka Holdings Co., Ltd. Announces Year-End Dividend for the Year Ended December 31, 2023, Payable on March 29 , 2024; Provides Second Quarter-End Dividend Guidance for the Fiscal Year 2024	Feb. 13	CI
Otsuka Holdings Lowers 2023 Profit Outlook	Feb. 13	MT
Japan's Nikkei cruises to 34-year peak, briefly breaching 38,000 range	Feb. 13	RE
Japan's Nikkei soars to 34-year high on chip shares, earnings	Feb. 12	RE
Phase 3 Trial for Otsuka's Alzheimer's-related Agitation Treatment Fails to Meet Primary Endpoint	Feb. 12	MT
Otsuka's drug for Alzheimer's disease agitation fails in late stage study	Feb. 12	RE
Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ended December 31, 2023	Feb. 12	CI
Ionis Pharmaceuticals Says Potential Angioedema Treatment Met Primary Endpoint of Phase 3 Study	Jan. 22	MT
Ionis Pharmaceuticals Signs Europe Licensing Deal With Otsuka for Donidalorsen in Hereditary Angioedema	Dec. 18	MT
Otsuka's Unit Remains as MicroPort Scientific's Thai Distributor Until 2026	Dec. 18	MT
Otsuka Unit Buys New York-Based Provider of Women Health Products	Dec. 05	MT
Nomura Adjusts Otsuka Holdings' Price Target to 6,800 Yen From 6,500 Yen, Keeps at Buy	Nov. 29	MT
Jefferies: Investor Interest Shifts from Daiichi Sankyo to Chugai and Otsuka Holdings	Nov. 27	MT
US FDA approves Medtronic's blood pressure treatment device for use	Nov. 17	RE
Aurinia Pharmaceuticals Partner Otsuka Pharmaceutical Files New Drug Application For Voclosporin in Japan	Nov. 13	MT

Chart Otsuka Holdings Co., Ltd.

Duration

Period

More charts

Company Profile

Otsuka Holdings Co, Ltd. is a holding company organised around 4 areas of activity: - manufacture and sale of pharmaceutical products (65.2% of sales): prescription drugs and intravenous solutions mainly for the treatment of central nervous system disorders, cancer, cardiovascular, gastrointestinal and ophthalmic diseases. In addition, the group sells diagnostic products and medical devices; - manufacture and sale of nutraceutical products (25.1%): functional foods and beverages, OTC products, nutritional supplements; - production of mineral waters, beverages and foods (2.1%); - other (7.5%): manufacture of functional chemicals and fine chemicals, provision of logistics services, manufacture of electronic products, etc. Net sales by source of income are divided between sales of products (93.8%), sales of licences and royalties (1.8%) and other (4.4%). Net sales are distributed geographically as follows: Japan (43.2%), North America (34%),

Sector

Pharmaceuticals

Calendar

2024-04-29 - Q1 2024 Earnings Release

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Otsuka Holdings Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

6,322 JPY

Average target price

5,982 JPY

Spread / Average Target

-5.38%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
OTSUKA HOLDINGS CO., LTD.	+19.87%	22.17B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.00%	44.31B
SANDOZ GROUP AG	+15.19%	14.62B
CIPLA LIMITED	+9.52%	13.12B
ZYDUS LIFESCIENCES LIMITED	+38.60%	11.58B
ONO PHARMACEUTICAL CO., LTD.	-8.96%	6.96B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+6.50%	5.03B
RICHTER GEDEON VEGYÉSZETI GYÁR NYILVÁNOSAN MUKÖDO RT.	-1.14%	4.27B

Generic Pharmaceuticals

Otsuka Holdings Co., Ltd.

Equities

4578

JP3188220002

Pharmaceuticals

Otsuka : Announcement of Changes in Company Officers at Otsuka Pharmaceutical Co., Ltd.

EPS Revisions